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Abstract
51Cr-labeled, superparamagnetic, iron oxide nanoparticles (51Cr-SPIOs) and 65Zn-labeled CdSe/CdS/ZnS-quantum dots (65Zn-
Qdots) were prepared using an easy, on demand, exchange-labeling technique and their particokinetic parameters were studied in
mice after intravenous injection. The results indicate that the application of these heterologous isotopes can be used to successfully
mark the nanoparticles during initial distribution and organ uptake, although the 65Zn-label appeared not to be fully stable. As the
degradation of the nanoparticles takes place, the individual transport mechanisms for the different isotopes must be carefully taken
into account. Although this variation in transport paths can bring new insights with regard to the respective trace element home-
ostasis, it can also limit the relevance of such trace material-based approaches in nanobioscience. By monitoring 51Cr-SPIOs after
oral gavage, the gastrointestinal non-absorption of intact SPIOs in a hydrophilic or lipophilic surrounding was measured in mice
with such high sensitivity for the first time. After intravenous injection, polymer-coated, 65Zn-Qdots were mainly taken up by the
liver and spleen, which was different from that of ionic 65ZnCl2. Following the label for 4 weeks, an indication of substantial degra-
dation of the nanoparticles and the release of the label into the Zn pool was observed. Confocal microscopy of rat liver cryosec-
tions (prepared 2 h after intravenous injection of polymer-coated Qdots) revealed a colocalization with markers for Kupffer cells
and liver sinusoidal endothelial cells (LSEC), but not with hepatocytes. In J774 macrophages, fluorescent Qdots were found colo-
calized with lysosomal markers. After 24 h, no signs of degradation could be detected. However, after 12 weeks, no fluorescent
nanoparticles could be detected in the liver cryosections, which would confirm our 65Zn data showing a substantial degradation of
the polymer-coated CdSe/CdS/ZnS-Qdots in the liver.
Beilstein J. Nanotechnol. 2015, 6, 111–123.
112
Introduction
Quantum dots (Qdots) are semiconductor nanocrystals
(2–100 nm in diameter) that combine a strong, size-tunable
photoluminescence with robust photostability, which makes
them a highly promising tool for various applications in
nanobioscience and nanomedicine [1-6].
Since many Qdots contain cadmium or other toxic elements, the
release of potential toxic metals is a major concern with respect
to biosafety. Many studies have demonstrated the toxicity of
various Qdots in cell culture [7-12]. However, when dosing was
applied under physiological conditions in mice and rats, no
abnormal behavior or tissue damage was observed over the
period of months after systemic administration of Qdots [13-
15]. Therefore, the relevancy of the in vitro data have been
called into question regarding the application in animals or even
for future application in humans [15,16]. The organ-specific
dose for in vivo experiments may not be high enough to induce
detectable acute toxicity. However, when Qdots are retained by
animals, long-term toxicity may be a problem. As a conse-
quence, the potential harmful effects of Qdots in vivo remain
unclear thus far, leaving many open questions. Future toxicity
studies should be more standardized and systematic, because
the methodological variability in the available literature to date
makes it difficult to compare and contrast results.
One important aspect in nanotoxicity evaluation is reliable
information on the distribution and metabolism for each indi-
vidual Qdot in vivo. To date, there exists only a limited number
of comprehensive studies concerning in vivo behavior of Qdots
[17-19]. One reason is the lack of appropriate techniques to reli-
ably quantify the dynamic variation of Qdots in living animals.
Fluorescent imaging has low spatial resolution and limited
penetration depth, and quantification based only on such
methods is limited.
Functionalized SPIOs are also interesting candidates for
nanomedical applications because of their magnetic properties
that allow specific targeting of early tumor or arteriosclerotic
lesions, which can be closely monitored by magnetic resonance
imaging (MRI). In contrast to Qdots, iron-based nanoparticles
are known to be less toxic given that iron is an essential trace
element and the iron transport pathways and the regulation of
iron homeostasis are quite well understood [20,21]. However,
similar to QDs, the fate of injected SPIOs is also still not
completely understood. The key problem again is the lack of a
reliable quantitative technique for in vivo studies. In MRI, the
correlation of the relaxation times to the local nanoparticle
concentrations is difficult due to possible agglomeration,
where the increase of hydrodynamic diameters caused by
opsonization and the difficulty in the quantification of the
degradation and the cellular uptake of particles [22,23]. In addi-
tion, most tissues contain substantial concentration of back-
ground iron that can be higher than the amount of injected
nanoparticulate iron.
For use in animal studies and for the eventual transfer to clinic-
al applications, more detailed information on the biocompati-
bility, in vivo kinetics, targeting efficacy and the acute as well
as the chronic toxicity of both nanoparticle systems is needed.
We are interested in techniques that allow the quantification of
nanoparticles in vivo and have already developed a post-syn-
thetic method to radiolabel the cores of superparamagnetic iron
oxide particles (SPIOs) [24]. In this sense, radiolabeling could
become a powerful tool for the full quantification of the partico-
kinetic details. However, it requires special equipment and
knowledge, and the selection of appropriate isotopes is critical.
We here report on the advantages and disadvantages of labeling
SPIOs and Qdots with heterologous radionuclides (65Zn for Cd,
51Cr for Fe) for the study of the distribution and degradation of
NPs in vivo.
Results and Discussion
Radiolabeling of 51Cr-SPIOs and 65Zn-Qdots
The cores of SPIOs and Qdots were radiolabeled with different
γ-emitting isotopes and basic parameters regarding their biodis-
tribution and degradation were studied. It was previously shown
that oleic acid-stabilized, hydrophobic, monodisperse, iron
oxide cores can easily incorporate water-free 59FeCl3 [24]. This
results in the stable labeling of the core and allows a quasi “on-
demand” synthesis of 59Fe-SPIOs designed for in vivo experi-
ments in animal models. It was coincidentally found that the
SPIOs could similarly be tagged with 51CrCl3, likely due to the
similarity between the Fe(III)- and Cr(III)-oxide chemistry. An
attempted incorporation of the divalent cation 65ZnCl2 in the
iron oxide core of SPIOs under similar experimental conditions
was unsuccessful. However, a distinct incorporation of 65ZnCl2
occurred when CdSe/CdS/ZnS core/shell/shell quantum dots
were synthesized (Figure 1).
Both hydrophobic nanoparticle cores were encapsulated using
the same polymer to render them water soluble. This resulted in
similar nanoparticles (comparable size, surface chemistry and
charge), despite the completely different core material. This was
proven when the biodistribution was compared using fluores-
cent Qdots and intravital microscopy in mice or MRI measure-
ments in mice and TEM in ex vivo samples for SPIOs (data not
shown). However, it should be noted that this type of radiola-
beling with nonidentical radionuclides (51Cr for Fe, 65Zn for
Cd) raises questions on the validity of the label data along the
transport and the degradation pathways of the particles.
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Figure 1: Postsynthetic labeling of quantum dots or SPIOs by incubation of monodisperse, oleic acid-stabilized core particles (CdSe/CdS/ZnS-
quantum dots, 5.5 or 7 nm; SPIOs, 11 nm) in chloroform with water-free 51CrCl3 or 65ZnCl2. The hydrophobic cores were then transferred into
aqueous medium by encapsulation with a well-characterized amphiphilic polymer, poly[maleic anhydride-alt-(1-octadecene)] (PMAOD).
51Cr-labeling of SPIOs
The exchange labeling with 51CrCl3 resulted in a stable and
homogenous labeling of the iron oxide core in the model SPIOs
as shown by fast protein liquid chromatography, filtration
experiments and the acid-catalyzed release of iron and 51Cr
(Figure 2).
When injected intravenously into mice, the 51Cr-labeled SPIOs
were taken up by the liver and spleen almost completely as seen
by the organ distribution results (Figure 3) two hours after
administration. The distribution of a trace dose of 51CrCl3 is
more pronounced in the blood and carcass and was overall very
different from the 51Cr-SPIOs. The short time distribution is in
good agreement with earlier results in rats, including also a
transient storage in bone [25].
The whole body retention (WBR) curve shown in Figure 4 for
51Cr-SPIOs clearly shows a lag phase of about 2 d, in which
51Cr was excreted from the whole body. Using a correction
term, a 2-compartment model was used for fitting which
resulted in a relatively short half-life of 12 d, and very long
half-life of ≈1000 d, which cannot be derived precisely from the
fit.
As a result, the 51Cr label seems adequate for labeling the
nanoparticles during blood passage and cell uptake. However,
as soon as intracellular degradation of the core takes place, the
different transport paths for Fe2+/Fe3+ and Cr3+ become a
consideration. Iron is dissolved from the iron oxide cores within
lysosomes under acid conditions, which then further reduces to
Fe2+ by Steap3 and is transported across the endosomal
membrane by the divalent metal ion transporter, DMT1 [26].
During iron homeostasis, excess iron would then be released by,
for example, macrophages via ferroportin, bound to apotrans-
ferrin and transported to cells in need for iron. The intracellular
processing of Cr3+ is more or less unknown, and even its physi-
ological role as a trace element is controversially discussed.
Supporters of its physiological role have suggested a function in
the form of a Cr3+-binding peptide, the so-called chromodulin,
occurring in carbohydrate, fat, or cholesterol, whereby metabo-
lism can increase insulin sensitivity in insulin-dependent cells
[27]. In this model, after interaction, Cr3+ would be excreted via
the kidneys and replaced by freshly absorbed Cr [28]. As shown
here by the 51Cr-WBR over 28 d, the excretion of 51Cr via the
kidneys and gastrointestinal tract is rather slow when using
51Cr-SPIOs and very different from 51CrCl3 (Figure 4). Excre-
tion of 51Cr from SPIOs was found mostly in feces and very
little in urine (data not shown). After 4 weeks, a small loss of
51Cr from the liver seems to be distributed mainly to the spleen,
gastrointestinal tract (GIT), and carcass, whereas from CrCl3,
51Cr accumulates in the liver. These results indicate a striking
different metabolism of Cr3+ from these two sources. We know
from previous experiments with the same SPIOs labeled with
59Fe instead of 51Cr that the iron oxide core of this particle is
degraded to a large extent in the liver (data not shown). We
therefore speculate here that the intracellular release of 51Cr is
trapped within the liver cells due to the lack of a specific Me3+
exporter.
Thus, our results could be interpreted as a new argument against
the role of Cr3+ as a physiological trace element. From this
perspective, the 51Cr labeling of SPIOs would present a novel
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Figure 2: Stability of 51Cr-radiolabeled SPIOs with a polymer shell.
(A) Size-exclusion chromatography (SEC) results of the polymer-
coated 51Cr-SPIOs. The radioactivity measured in fractions corre-
sponds to the elution of the NPs measured by UV absorption at
280 nm. (B) Release of 51Cr3+ from radiolabeled nanoparticles when
incubated with 0.1 M HCl at room temperature. A centrifuge was used
for the separation of released chromium ions (filtrate) from nanoparti-
cles (filter) at distinct times during the degradation of the particles.
(C) Release of Fe3+ and 51Cr3+ from degraded iron oxide cores was
measured in the filtrate via atomic absorption spectrometry and 51Cr-γ-
counting. The results indicate the constant release of iron and
chromium over time during the degradation of the particles.
way to bring 51Cr into cells and to study possible transport
paths of this element, however, it seems less appropriate to
study the fate of SPIOs in vivo. However, we present here an
interesting application in which the differences between the
metabolism of iron and chromium can be elegantly used to
study the absorption of intact nanoparticles from the gastroin-
testinal tract, an important topic in nanotoxicology. For this,
59Fe-labeled SPIOs were given by gavage to groups of mice
and the 59Fe-WBR was followed in living mice for 14 d using a
whole body counter (Figure 5A). Most of the activity was lost
Figure 3: Distribution and degradation of 51Cr-SPIOs in comparison
with 51CrCl3 after intravenous injection in groups of mice (n = 4).
(A) 51Cr activity in organs and tissue 2 h and (B) 4 weeks (4 w) after
injection. Data are presented as mean values ± standard error of the
mean. Asterisks indicate significant differences (p < 0.05).
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Figure 4: Whole body retention (WBR) of 51Cr-SPIOs and ionic chromium after intravenous injection. The fitted curve of 51CrCl3 follows a standard
triple exponential decay curve for a 3-compartment model (transport, transit, storage pool, with half-life 0.2, 2.1, ≈65 d).
Figure 5: Absorption of 59Fe- or 51Cr-labeled SPIOs in mice. (A) 59Fe-
labeled polymer-coated SPIOs or so-called “nanosomes” (oleic acid-
stabilized, hydrophobic SPIOs embedded in chylomicron-like lipid
micelles) [29] were administered by gavage to groups of mice
(n = 4–5). The 59Fe-WBR was measured after 1–14 d. (B) The same
procedure as with 51Cr-labeled SPIOs, “nanosomes” and 51CrCl3 (n =
8). Values of the respective 51Cr-WBR for each individual mouse is
given at day 7 day (which is taken as the apparent gastrointestinal
51Cr absorption).
via fecal excretion within the first 3 d, which is typical for
rodents. The 59Fe-WBR at days 7–10, a well-accepted para-
meter for the intestinal iron absorption, showed a small but
significant absorption rate of about 5% of the dose (Figure 5A).
The problem is that substantial amounts of ionic iron can also
be absorbed in the duodenum by the physiological absorption
mechanism via DMT1. Therefore, the 59Fe-results can simply
be interpreted as a partial digestion of the SPIOs in the stomach
followed by the absorption of released ionic Fe2+ and do not ne-
cessarily show the absorption of intact nanoparticles.
The use of 51Cr-labeled SPIOs can clarify this point, because it
was shown earlier that the intestinal absorption of ionic Cr3+ is
extremely low in rodents [25,30]. When 51Cr-labeled SPIOs
were orally administered to groups of mice, no absorbed activi-
ties were detected from polymer-coated SPIOs or from oleic
acid-stabilized, lipophilic SPIOs embedded in lipid micelles
(Figure 5B, “nanosomes”). The measured 51Cr values were
significantly lower (p < 0.01) as compared to a trace dose of
orally administered, aqueous CrCl3, indicating that only a very
limited amount (<0.05%) of the administered dose from intact
particles can be absorbed in the intestinal tract. This excludes a
relevant, unspecific particle uptake in the intestinal tract, at least
for particles of this type (size, charge).
It should be noted that the results obtained with lipid micelles
are also relevant for the field of dietary fat absorption in the
intestinal tract, and would support the classical view of fatty
acid absorption from micelles formed in the gastrointestinal
tract after food intake. The action of bile acids and pancreas
lipase would first produce free fatty acids or monoglycerides,
but obviously does not include the absorption of intact micelles
into enterocytes [31].
65Zn-labeling of quantum dots
For intrinsic labeling, a variety of radionuclides can be incorpo-
rated into quantum dots consisting of cadmium, copper, indium,
zinc, selenium, and tellurium. Although cadmium is the most
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relevant, it has no adequate radioisotope that would allow for
easy availability and optimal detection for in vivo studies.
Therefore, studies with 109Cd are rare. However, in a recent
proof of principle study, this radionuclide was used to synthe-
size CdTeSe/109CdZnSe and to study the distribution in mice up
to 7 d [32].
In the present study the outer ZnS shell of CdSe/CdS/ZnS
(core/shell/shell) quantum dots was labeled by incubation with
water-free 65Zn2+ in an organic solvent. This radionuclide is a
hard γ-emitter (1.1 MeV), which would allow precise measure-
ment even in living animals using a whole body counter.
Precipitation with methanol revealed that over 70% of the
radioactivity was localized within the Qdot-mass, which hints at
the accumulation of the isotope in the outer shell. Stability tests
of the polymer-coated Qdots included dialysis, size-exclusion
chromatography (SEC) and filtration techniques. Dialysis took
place against phosphate buffered saline (PBS) and the buffer
was changed every 24 h (Figure 6A). Around 30% of the
radioactivity was found in the dialysate after 24 h. Only around
4% of the radioactivity was detected in the removed buffer after
48 h. Similar results were obtained for samples taken at 72 h
and 96 h. The amount of radioactivity that was released into the
buffer after the first 24 h could be attributed to free 65Zn ions
from the encapsulation technique. Further loss of the label
during the course of time could indicate a small but continuous
bleeding of the radioactive isotope. These results were
confirmed by filtration using a centrifuge to concentrate the
probes (Figure 6B).
Radiolabeled Qdots were filtered and thereby separated from
free 65zinc ions. The concentrated Qdots were resuspended and
the filtration procedure was repeated twice. 22.6, 10.6 and 5.4%
of the radioactivity was found in the filtrate after the first,
second and third filtration. The SEC of the radiolabeled,
hydrophilic Qdots shows that the particles basically elute after
24 min (Figure 6C). It can be clearly seen that most of radioac-
tivity is colocalized with the nanoparticles. Nevertheless, there
was also a fraction of ionic 65Zn that eluted after 40 min and
cannot be completely separated by centrifugal filtration due to
the slight continuous bleeding of the label (or the dissolution of
the ZnS shell).
Pharmacokinetic measurements of 65Zn-
labeled Qdots
Despite the described stability problems of the 65Zn-label, the
radiolabeled Qdots were used to investigate basic pharmacoki-
netic properties under these conditions. Zinc is a well-known
trace element and widely used as a catalytic or structural
cofactor in about 3000 human zinc proteins [33,34]. At least 14
speciﬁc transporters are responsible for either zinc inﬂux or
Figure 6: Stability of 65Zn-radiolabeled Qdots with a polymer coating.
(A) Dialysis of 65Zn-radiolabeled and polymer-coated Qdots. The
Qdots were transferred to a dialysis tube and the dialysis buffer was
removed every 24h and tube and buffer were measured. 65Zn appears
not to be stably incorporated: there is small release (≈4%/24h) of
65Zn2+ ions. (B) SEC of 65Zn-radiolabeled and polymer-coated Qdots.
(C) Desalting of Qdots in a 10 kDa centrifugal filter unit. The radioac-
tivity in the filtrate indicates a slight loss of the radioactive label. The
resuspension and filtration of the Qdots was repeated two times. The
black line shows the elution profile of the nanoparticles whereas the
red line represents the profile of the activity of 65Zn. Nanoparticles and
radioactivity are located in the same fraction (24 min), although
unbound 65Zn ions can also be found (40 min) directly after filtration.
efﬂux in mammalian cells [35]. Detailed compartment models
of zinc kinetics in humans and mice are available [36,37]. As
cadmium and zinc both belong to the group IIB of the periodic
Beilstein J. Nanotechnol. 2015, 6, 111–123.
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table, they form tetrahedral complexes and compete for the
same binding sites and/or ligands in biological systems [38].
Their interaction is probably one of the most recognized
metal–metal interactions, which could make 65Zn as acceptable
marker also for Cd metabolism. The organ distribution 2 h after
administration shows the liver and the spleen are the major
uptake organs for Qdots with around 70% of the injected dose
present (Figure 7A). This is in good agreement with the results
from Sun et al. [32] and supports the reliability of our label
results.
When CdSe/CdS/ZnS (core/shell/shell) quantum dots are
degraded in vivo, the outer shell will be dissolved first and zinc
will be released into the system. The Qdot distribution in organs
2 h and 4 weeks after intravenous injection was investigated. To
compare the data to a physiological distribution of zinc,
65ZnCl2 was used as a control against 65Zn-radiolabeled Qdots.
As discussed earlier, this is a necessary control for studying the
fate of any given degradable particle. In an autoradiographic
study, the highest uptakes after 2 h were found in the liver,
pancreas, spleen, kidneys and the intestinal walls, which is in
good agreement with our values for ZnCl2 shown in Figure 4
[39]. However, also in short-time experiments, the liver is not
the main storage organ for ionic Zn and as became obvious
from the short-time distribution of the 65Zn-label between
65ZnCl2 and 65Zn-Qdots. Zn has a fast turnover, and the
majority of the 65Zn label is removed after 4 weeks from all
organs that have fast exchange kinetics and remains stored in
tissue with low exchanges rates (such as bones and skin). Organ
distribution of 65Zn-labeled Qdots and a trace 65Zn dose 4
weeks after intravenous injection was found to be similar for
most of the organs and tissue, with the exception of the liver
and spleen. This indicates that radioactivity in the form of
Qdots is stored in these organs, and the particles are thus not
fully degraded. Otherwise, 65Zn released by degradation of the
nanocrystals was distributed between all organs in a manner
comparable to that of the ionic 65ZnCl2. In contrast to the
chromium results discussed above, 65Zn from CdSe/CdS/ZnS-
Qdots shows a similar whole body retention compared with
65ZnCl2 (Figure 8).
Distribution of Qdots within the liver
Since the radiolabeled Qdots show that the liver is the major
uptake organ of the analyzed nanomaterials, a closer look at the
distribution of Qdots among different liver cells was warranted.
Therefore, polymer-coated Qdots were injected and the mice
were observed two hours after intravenous injection into the tail
vein and cryosections of the liver were prepared (Figure 9).
It is well-established that liver sinusoidal endothelial cells
(LSECs) carry out a scavenger function by expressing several
Figure 7: Organ distribution of Qdots and ionic zinc after intravenous
injection into the tail vein of mice. 65Zn activity was measured in
organs and tissue. The percentage distribution of polymer-coated
Qdots and ionic zinc 2 h (A) and 4 weeks (4 w) (B) after application is
shown. The liver and spleen have the highest specific activity when
Qdots are applied. The data are presented as mean values ± standard
error of the mean.
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Figure 8: Whole body retention of Qdots and ionic zinc in mice (n = 4). Curves indicate fits using a triple exponential decay function for a 3-compart-
ment model. Similar half-lives with different fractions were found for Qdots (0.9, 6, 41 d, with fractions 19.1, 19.6, and 41%) and ZnCl2 (0.3, 6.7, 35 d,
11.9, 41, and 35%). Nevertheless, the difference between the curves is significant (p < 0.05), indicating an incomplete degradation of particles in the
liver.
Figure 9: Confocal microscopy of a cryosection of a rat liver 2h after intravenous injection of polymer-coated Qdots. The nuclei are stained with DAPI.
Immunostaining of Kupffer cells (KCs, anti-CD31) and liver sinusoidal endothelial cells (LSECs, with anti-CD68) was performed. Regions outlined by
the white boxes are magnified in the lower panels. Nanoparticles can be found located in endothelial cells (A) as well as in Kupffer cells (B), but not in
hepatocytes. Scale bar: 20 µm for the upper panel, and 5 µm for the magnified images.
Beilstein J. Nanotechnol. 2015, 6, 111–123.
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Figure 10: Colocalization of Qdots and lysosomes. J774 cells were incubated with Qdots (red) for 2 h and fixed afterwards (upper row) or 24 h later
(lower row). Cells were immunostained with anti-LAMP1 (detected with Cy2, green). The “Merge” images show that Qdots are localized in lysosomes
(yellow). Scale bar: 50 µm.
types of scavenger receptors and that Kupffer cells (KCs)
belong to the family of macrophages and form part of the retic-
uloendothelial system. Thus, the sections were analyzed by
immunofluorescence and stained for hepatic endothelial cells
and Kupffer cells, which are known to play important roles in
endocytosing processes and are known to be among the most
prominent cell types which take up protein-corona-covered
nanoparticles [22,40]. The confocal images of the cryosections
exhibit the cell distribution within the liver and confirm this
hypothesis. Internalized Qdots colocalize with LSECs as well as
with KCs. To date, polymer-coated Qdots were not found in
hepatocytes. Since the surface chemistry of the Qdots and
SPIOs is identical when coated with the amphiphilic polymer,
the cell distribution should be similar.
Intracellular processing of Qdots
Further insight into the cellular internalization and processing of
polymer-coated Qdots and SPIOs was gained by cell culture.
For comparison of the in vivo data, these studies were made
with J774 cells (a murine macrophage cell line). The cells were
incubated with polymer-coated Qdots for 2 h, then the nanopar-
ticles were removed, and the cells were rested for 24 h. The
cells were checked for degradation, which would be indicated
by decreasing fluorescence over time due to cell division
(Figure 10).
When cells were fixed directly after incubation, the red fluores-
cence of the Qdots was found to colocalize with the green fluo-
rescence from lysosomes labeled with the LAMP1 antibody,
which indicates that the nanoparticles accumulate in the
lysosomes. When the cells were fixed 24 h later, the Qdots
fluorescence still colocalizes with lysosomes and does not
show evidence of degradation, meaning that the possible degra-
dation process seems too slow to be followed by a change in
fluorescence.
However, in a group of mice, the liver cryosections were
repeated 12 weeks after intravenous injection. Here no further
localizable fluorescence was observed, indicating that most of
the Qdots in the liver were at least partially degraded, resulting
in a loss of fluorescence. This would otherwise confirm the
65Zn results, however, this was in contrast to Yank et al. who
followed commercial PEG 5000-coated CdTe/ZnS Qdots by
tracing their fluorescence in mice for 28 d and measured 111Cd
by inductively coupled plasma–mass spectrometry (ICP–MS)
[41]. In this study, they found high levels of cadmium in the
spleen, liver, and kidneys. Additionally, Su et al. found persis-
tent, initial, high cadmium concentrations in the liver and
spleen, which remained at high levels even after 80 d [42].
However, in both these studies, the cadmium concentrations in
organs cannot directly be substituted for intact Qdots, and
differences in Cd concentrations between organs would not ne-
cessarily indicate a redistribution of particles in vivo. So far, to
our knowledge, the export of nanoparticles from living cells
may occur as single particles crossing barriers, but this has
never been directly observed for a flux of particles.
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Conclusion
The present study highlights the importance of reliable quantifi-
cation methods for in vivo studies involving quantum dots.
Radiolabeling could provide such quantification, preferentially
by introduction of an appropriate radionuclide into the core or
an inner shell during chemical synthesis in order to guarantee
the full stability of the label.
Experimental
Nanoparticle synthesis
Monodisperse, oleic acid-stabilized SPIOs were synthesized
according to Yu et al. [43]. Briefly, a mixture of 2 mmol
FeOOH, 8.0 mmol oleic acid and 22 mL of 1-octadecene was
held at 320 °C under nitrogen for about 80 min. The 11 nm core
diameter particles showed a narrow size distribution (less than
10% standard deviation) as confirmed by transmission electron
microscopy (TEM). Encapsulation with the PMAOD solution
was achieved using a sonification method as described in [24].
From the measured iron content, the diameter of the core
(11 nm) and the assumed core material (Fe2O3), the molar
concentration of an aqueous solution was calculated.
CdSe/CdS/ZnS (core/shell/shell) quantum dots with red (7 nm
diameter) or green (5.5 nm) fluorescence were synthesized as
described in [29]. This was done as a one-pot synthesis using a
mixture of hexadecylamine (HDA), trioctylphosphine oxide
(TOPO), and trioctylphosphine (TOP) as a stabilizing solvent,
following the techniques described by Mekis [44]. As the core
size of Qdots is directly related to the excitonic peak in the
UV–vis absorption spectrum, the size-dependent molar extinc-
tion coefficient for the CdSe core was determined using the
following empirical formula [45]: D = (1.6122∙10−9)λ4 −
(2.6575∙10−6)λ3 + (1. 6242∙10−3)λ2 − (0.4277)λ + 41.57.
Radioactive labeling SPIOs and Qdots
The radionuclides were purchased from Perkin-Elmer, Rodgau,
Germany (51CrCl3 in 0.5 HCl, specific activity: 700 mCi/mg;
65ZnCl2 in 0.5 N HCl, specific activity: 4.32 mCi/mg).
For the radiolabeling of SPIOs, similar to that previously
described [24], aliquots of 51CrCl3 (40–80 µCi, 0.3–0.6 µg Cr)
were lyophilized to remove water and traces of hydrochloric
acid. Next, previously synthesized, monodisperse, oleic acid-
stabilized SPIOs were added (1 mg dry weight in 400 µL
CHCl3). The solution was stirred at room temperature for at
least 24 h before using the SPIOs for further experiments (i.e.,
embedding in lipid micelles or polymer coating).
For the synthesis of the 65Zn-Qdots, an aliquot of an acidic
65ZnCl2 solution (20–40 µCi, 13–25 µg Zn) was lyophilized to
dryness, and a solution of lyophilic Qdots in chloroform was
added and stirred at room temperature for 24 h. The same
polymer as described above was used for the transfer into
aqueous solution.
As control solutions, 100 µL of aqueous 51CrCl3 (per mouse
1.5–3.0 µCi, 14 ng Cr) or aqueous 65ZnCl2 (per mouse
2–2.6 µCi, 1.3–1.8 µg Zn) was intravenously injected. For
the animal experiments, the applied Cr content in the
injected volumes was completely negligible as compared
to the natural concentration of Cr(III) found in a mouse. The
specific activity of the 65Zn solutions available were already
rather low, however, the applied nominal Zn content/per
mouse (0.2–1.8 µg Zn) was also well below the daily flux of
Zn within a mouse from the uptake due to a normal diet of
260 µg Zn [35-37].
Size-exclusion chromatography (SEC)
Similar to that previously described in [24], SEC was performed
using a Superose-6 10/300 GL column (Amersham Bioscience,
Munich, Germany) with buffer (10 mM tris(hydroxy-
methyl)aminomethane, 0.15 mM NaCl, 10 mM EDTA) at a
flow rate of 0.5 mL/min. Particle detection was achieved via
UV absorption at 280 nm.
For iron detection, 200 µL of each fraction was treated with
50 µL of 5 M hydrochloric acid at 70 °C for 30 min. After-
wards, 150 µL of a 2 M acetate buffer (pH 4.8) containing
10% ascorbic acid was added to 50 µL of each fraction, fol-
lowed by 100 µL of a solution of 50 mg bathophenanthroline in
50 mL water. After 15 min, the absorption was measured at
540 nm.
Radioactivity measurements
51Cr- and 65Zn-activity in living mice or tissue samples were
measured using the Hamburg whole body radioactivity counter.
The whole body retention of 51Cr or 65Zn was measured at
given time points in a 200 cm long, 4π geometry, whole body
radioactivity detector with a liquid organic scintillator in the
energy range from 980–3,000 keV [46]. The respective mouse
was placed in a cage in the middle of the counter. The influ-
ence of the movement of the animal during the measurement
(1–6 min) was negligible due to the large dimension of the
counter. After intravenous application, repeated measurements
of the 51Cr or 65Zn activity were performed over the course of
28 d (Figure 4 and Figure 8) and are a quantitative measure of
the excretion of the specific isotope through feces and urine.
After oral administration, the whole body retention after 7–14 d
is a well-accepted measure of the intestinal absorption of the
isotopes in the respective galenic formulation, because non-
absorbed material is completely excreted at that time via the
feces.
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In vivo studies
All animal experiments were approved by the local committee
for animal experiments (Behörde für Soziales, Familie, Gesund-
heit und Verbraucherschutz, BSG, Hamburg Tierversuchs-Nr.
34/10).
Wild type FVB/N mice were injected with 100–200 µL of a
solution containing either 51Cr-SPIOs (per mouse: 50–100 µg,
Fe = 25–50 pmol particles, molar ratio 51Cr:Fe = 1:1700–3400)
or 65Zn-Qdots (per mouse: 50–100 pmol, with 0.1–0.3 µg Zn
and 0.2–0.35 µCi 65Zn) into the tail vein. The activity,
measured immediately after administration of the radiolabeled
compounds in the whole body, was taken as the 100% refer-
ence value. At 120 min or 4 weeks after injection, the mice
were anaesthetized (Rompun/Ketamine), blood was removed by
cardiac puncture, and the organism was perfused with PBS
containing 10 units of heparin. The blood and the organs
(spleen, kidney, liver, etc.) were removed and weighed and the
radioactivity was measured.
To prepare cryosections of the liver, the mice were anaes-
thetized after 2 h after administration of Qdots, and the
organism was perfused with PBS containing 4% PFA and 5%
sucrose. The liver was removed and allowed to further rest for
60 min on ice. Tissue sections of 10 µm thicknesses were cut
from frozen specimens embedded in an optimum cutting
temperature formulation solution (Sakura Finetek Europe).
Cryosections were mounted on a slide (Superfrost/Plus,
Glaswarenfabrik Karl Hecht KG, Sondheim, Germany) and
dried overnight before immunostaining.
Cell culture
J774 cells were cultured on microscope cover glasses (13 mm
diameter, Glaswarenfabrik Karl Hecht KG, Sondheim,
Germany) in DMEM medium (10% FCS, 4.5 g/L glucose,
[+]glutamine, [−]pyruvate, 1% antimycotic–antibiotic from
Invitrogen). The cells were incubated at 37 °C in a humidified
atmosphere containing 5% CO2. For uptake analysis, the
J774 cells were seeded onto 24-well plates at a density of
100,000 cells/well and allowed to grow for 2 d. Typically, the
cells were incubated with 500 µL of medium containing Qdots
(8.4 nM) at 37 °C. After 2 h, the medium was removed from
each well and fixed with 4% PFA or the cells were allowed to
rest for another 24 h before fixing for immunofluorescence
studies.
Fluorescent immunostaining
For immunostaining, the cryosection slides were blocked with
1% BSA in PGS (PBS, 0.5 mg/mL saponin, 5 mg/mL glycine)
for 1 h at room temperature. After blocking, the slides were in-
cubated with the respective primary antibodies at 4 °C
overnight. Afterwards, the slides were washed three times with
PGS followed by incubation with secondary antibodies for 2 h
at room temperature.
For in vitro immunofluorescence studies, cells were likewise
blocked with 1% BSA in PGS for 1 h at room temperature, fol-
lowed by incubation with primary antibody for 1 h at 37 °C and
three washes with PGS. Incubation with secondary antibody
was performed for 45 min at 37 °C.
The following antibodies and dilutions were used: rabbit anti-
CD31 (1:50, Abcam), mouse anti-Lamp1 (1:200, Develop-
mental Studies Hybridoma Bank) and rat anti-CD68 (1:100,
Abcam); Cy3 anti-rabbit (1:100, Jackson Immuno Research
Laboratories), Alexa 488 anti-mouse (1:250, Jackson Immuno
Research Laboratories) and Alexa 647 anti-rat (1:50; Jackson
Immuno Research Laboratories). Nuclei were stained with
DAPI.
Data analysis
To assess the statistical significance between results in different
groups of mice, the two-tailed, unpaired, Student’s t-test was
performed, where the parameter P < 0.05 was considered as
significant.
Slide Write Plus 7.0 software (Advanced Graphics Software
Inc., Encinitas, USA) was used to fit the data for the whole
body retention in mice (Figure 4 and Figure 8).
The mean values of the 51Cr or 65Zn retention data R(t) from
whole body counting were fitted by a 3-compartment model
(1)
where the fractions A1 + A2 + A3 = 100% and the corres-
ponding half-lives are .
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